Compare · NVO vs RAPP
NVO vs RAPP
Side-by-side comparison of Novo Nordisk A/S (NVO) and Rapport Therapeutics Inc. (RAPP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RAPP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 87.8x RAPP ($2.46B).
- Both names hit the wire about 9 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 12 for RAPP).
- Company
- Novo Nordisk A/S
- Rapport Therapeutics Inc.
- Price
- -
- -
- Market cap
- $215.46B
- $2.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 9
- 9
- Recent ratings
- 25
- 12
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest RAPP
- Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
- Chief Development Officer Yeleswaram Krishnaswamy sold $20,160 worth of shares (404 units at $49.90) as part of a pre-agreed trading plan, decreasing direct ownership by 0.16% to 246,022 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Rapport Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Rapport Therapeutics Inc.
- Chief Executive Officer Ceesay Abraham sold $2,433,176 worth of shares (51,499 units at $47.25) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 486,108 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Rapport Therapeutics Inc.
- SEC Form 10-Q filed by Rapport Therapeutics Inc.
- Rapport Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
- Chief Executive Officer Ceesay Abraham sold $93,061 worth of shares (2,210 units at $42.11) as part of a pre-agreed trading plan, decreasing direct ownership by 0.41% to 537,607 units (SEC Form 4)